Press release 📈 Stocks 🌍 Denmark

Novo Nordisk Presents Real-World Wegovy Data on Food Noise at ObesityWeek

Q: Does this new Wegovy data change Novo Nordisk's financial outlook?

The article contains no revenue or profit figures and no guidance change; it only reports real-world study results on food noise reduction presented at ObesityWeek 2026.

Q: How strong is the evidence from these studies?

Both SIGNAL and OCTANE are retrospective analyses of telehealth data that show associations only, with self-reported scores and possible selection bias, so they cannot prove causality.

Novo Nordisk reported real-world data at ObesityWeek 2026 showing Wegovy injection and oral semaglutide are associated with reduced food noise, with the OCTANE study noting a 25% reduction in scores over three months.

📅 November 14, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: NVO → 2/10 (55% confidence).

📊 Affected Assets (1)

NVO

Neutral 🤖 55%

📅 Short-term 🌍 DK · Explicit

Novo Nordisk presented real-world ObesityWeek 2026 data on Nov 14, 2026 showing semaglutide (Wegovy injection and oral) reduced food noise scores, e.g. ~25% reduction over 3 months in OCTANE (p<0.001). This supports the drug's patient-centered appeal but is retrospective, association-only evidence with self-reported data, and contains no revenue, guidance or comparable financial figure.

Catalysts

• SIGNAL study: food noise score reduction of -0.42 points in month 1 and -0.72 points at 6 months in 26,213 adults
• OCTANE study: ~25% reduction in oral semaglutide food noise scores over 3 months (2.8 to 2.1, p<0.001)

Risk Factors

• Real-world studies show associations only and cannot determine causality
• Self-reported data, selection bias from treatment persistence, limited generalizability

🧭 Full analysis of these assets

🎯 Key Takeaways

The SIGNAL study of 26,213 adults showed semaglutide injection reduced food noise scores by 0.72 points at six months.
The OCTANE study reported a 25% reduction in average food noise scores for oral semaglutide users over three months.
At three months, 86.4% of OCTANE participants reported at least one treatment improvement, including better-fitting clothing and increased energy.
Both studies are retrospective analyses of telehealth data and cannot determine causality due to potential self-reporting and selection biases.

📝 Executive Summary

Novo Nordisk unveiled real-world findings from the SIGNAL and OCTANE studies at ObesityWeek 2026, demonstrating that Wegovy injection and oral semaglutide are associated with reductions in "food noise." The retrospective analyses, conducted via the Ro telehealth platform, showed significant decreases in intrusive thoughts about food among adults with obesity or overweight, marking an emerging area of research for the company.

❓ FAQ

Does this new Wegovy data change Novo Nordisk's financial outlook?

The article contains no revenue or profit figures and no guidance change; it only reports real-world study results on food noise reduction presented at ObesityWeek 2026.

How strong is the evidence from these studies?

Both SIGNAL and OCTANE are retrospective analyses of telehealth data that show associations only, with self-reported scores and possible selection bias, so they cannot prove causality.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article